高级检索
杨倩, 汪小涧. 鞘氨醇激酶1抑制剂的研究进展[J]. 中国药科大学学报, 2021, 52(6): 759-768. DOI: 10.11665/j.issn.1000-5048.20210615
引用本文: 杨倩, 汪小涧. 鞘氨醇激酶1抑制剂的研究进展[J]. 中国药科大学学报, 2021, 52(6): 759-768. DOI: 10.11665/j.issn.1000-5048.20210615
YANG Qian, WANG Xiaojian. Research progress of sphingosine kinase 1 inhibitors[J]. Journal of China Pharmaceutical University, 2021, 52(6): 759-768. DOI: 10.11665/j.issn.1000-5048.20210615
Citation: YANG Qian, WANG Xiaojian. Research progress of sphingosine kinase 1 inhibitors[J]. Journal of China Pharmaceutical University, 2021, 52(6): 759-768. DOI: 10.11665/j.issn.1000-5048.20210615

鞘氨醇激酶1抑制剂的研究进展

Research progress of sphingosine kinase 1 inhibitors

  • 摘要: 鞘氨醇激酶1(SphK1)是调控细胞膜脂质微环境的重要蛋白,在神经酰胺,鞘氨醇和鞘氨醇-1-磷酸的动态平衡中发挥重要作用。SphK1的过度表达与肿瘤的发生,发展和迁移过程以及产生耐药性有着密切的联系。SphK1抑制剂可以诱导多种肿瘤细胞凋亡,并且可以逆转肿瘤耐药性,具有良好的药物开发前景。本文综述了SphK1的结构生物学以及SphK1抑制剂的结构类型和构效关系研究进展。

     

    Abstract: Sphingosine kinase 1 (SphK1) is an important protein that regulates the lipid microenvironment of cell membranes, and plays an important role in the dynamic equilibrium of ceramide, sphingosine and sphingosine-1-phosphate.The overexpression of SphK1 is closely related to the occurrence, development and migration of tumors as well as the generation of drug resistance.SphK1 inhibitors can induce apoptosis of various tumor cells and reverse drug resistance, which has a good prospect for drug development.In this article, the structural biology of SphK1, the structural types and structure-activity relationships of SphK1 inhibitors are reviewed.

     

/

返回文章
返回